Table 3.

Incidence of adverse events evaluated by propensity score matching.

Adverse events	Before propensity score matching (full patient cohort)				After propensity score matching (propensity score matched patient cohort)
	Favipiravir (n = 888)	Standard treatment (n = 149)	Estimated difference (95% CI)a	p-valueb	Favipiravir (n = 149)	Standard treatment (n = 149)	Estimated difference (95% CI)a	p-valueb
Nausea	71 (8.0)	20 (13.4)	− 5.4 (− 12 to − 0.5)	0.030	16 (10.7)	20 (13.4)	− 2.7 (− 10.1 to 4.8)	0.477
Vomiting	27 (3.0)	11 (7.4)	− 4.3 (− 9.8 to − 0.9)	0.009	7 (4.7)	11 (7.4)	− 2.7 (− 8.3 to 3.0)	0.331
Diarrhea	122 (13.7)	20 (13.4)	0.3 (− 6.4 to 5.5)	0.917	24 (16.1)	20 (13.4)	2.7 (− 5.5 to 10.7)	0.514
Eye discoloration	23 (2.6)	5 (3.4)	− 0.8 (− 5.1 to 1.5)	0.584	3 (2.0)	5 (3.4)	− 1.3 (− 5.4 to 2.7)	0.474
Jaundice	9 (1.0)	3 (2.0)	− 1.0 (− 4.8 to 0.6)	0.396	0 (0.0)	3 (2.0)	− 2.0 (− 4.9 to 0.9)	0.082
Arthralgia	52 (5.9)	9 (6.0)	− 0.2 (− 5.4 to 3.1)	0.929	11 (7.4)	9 (6.0)	1.3 (− 4.5 to 7.2)	0.643
Palpitation and sweating	67 (7.5)	14 (9.4)	− 1.9 (− 7.8 to 2.3)	0.436	10 (6.7)	14 (9.4)	− 2.7 (− 9.0 to 3.7)	0.394
Abdominal pain	14 (1.6)	2 (1.3)	0.2 (− 3.2 to 1.7)	1.000	0 (0.0)	2 (1.3)	− 1.3 (− 3.9 to 1.2)	0.156
Dizziness	84 (9.5)	19 (12.8)	− 3.3 (− 9.8 to 1.6)	0.214	13 (8.7)	19 (12.8)	-4.0 (− 11.1 to 3.1)	0.262
Difficult breathing	37 (4.2)	9 (6.0)	− 1.9 (− 7.0 to 1.3)	0.304	4 (2.7)	9 (6.0)	− 3.4 (− 8.2 to 1.6)	0.156
Facial edema	8 (0.9)	1 (0.7)	0.2 (− 2.8 to 1.3)	1.000	2 (1.3)	1 (0.7)	0.7 (− 2.2 to 3.5)	0.562
Allergic rash	39 (4.4)	7 (4.7)	− 0.3 (− 5.1 to 2.6)	0.867	8 (5.4)	7 (4.7)	0.7 (− 4.5 to 5.9)	0.791

NA data not applicable; coronavirus disease-2019, n number.

Data are presented as numbers (%).

^aAn estimated difference is the difference in proportions shown for favipiravir compared to the control.

^bp-value corresponds to the Chi-square test or Fisher’s exact test.